Release
📈 Stocks
Sobi Reports Positive Phase 3 Results for Gout Drug Candidate Pozdeutinurad
(12 days ago)
Sobi shares gain momentum as the company reports successful Phase 3 REDUCE-2 trial results, confirming the efficacy and safety of its investigational…